RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational ...
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma Patients were enrolled in the HOVON-902 prospective cohort and received curative-intent ...
As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective alternatives for patients who respond inadequately to standard first-line treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results